Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric citrate for hyperphosphatemia in Chinese maintenance hemodialysis patients
ChiCTR2400083534Phase 3Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric citrate in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Change in serum phosphorus from baseline at week 12. Started Apr 2024; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2400083534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083534.